Key Points

Parabilis and one additional recent IPO each surpassed Moderna, which held the record for the largest biotech IPO previously.
Parabilis technology has potential to transform treatments and apply across multiple disease categories.
These 10 stocks could create the next group of millionaires

This year has proven exceptional for initial public offerings, led by Cerebras Systems with the largest to date and SpaceX positioned for the all-time biggest launch. Anthropic and OpenAI have also submitted confidential regulatory filings, pointing to possible market entries in the near term.

While much activity centers on technology, biotech stands out as another strong sector. Kailera Therapeutics started the momentum in April by completing a biotech IPO larger than the previous record set by Moderna at 604 million dollars in 2018. This week Parabilis Medicines topped that mark with 670 million dollars raised. Shares climbed 58 percent on the opening trading day to finish slightly above 31 dollars.

Will AI produce the first trillionaire globally? Our group issued a fresh analysis on the lesser-known firm known as an Indispensable Monopoly that supplies essential technology required by both Nvidia and Intel. Continue

Market participants express strong interest in this biotech firm pursuing a novel method to address cancer and other illnesses. The central question remains whether buying the stock after such a strong IPO debut makes sense.

Image source: Getty Images.

Addressing previously untreatable targets

Parabilis began operations in 2015 based on extensive prior work from Greg Verdines laboratory at Harvard University. Verdine served as a co-founder and initial chief executive. His group developed an approach to engage proteins inside cells that lack suitable binding surfaces, previously viewed as untreatable by standard drugs.

The team engineered a new class of therapeutics by shaping peptides into an alpha-helix structure. This design enables cell entry, attachment to flat protein surfaces, and disease intervention. The result became the company Helicon platform.

Mathai Mammen, previously global research and development leader at Johnson and Johnson where he guided approvals for nine medicines in oncology, immunology, and neuroscience, now serves as chief executive. His background positions him well to advance Parabilis through ongoing trials and eventual product launches.

Encouraging outcomes observed in patients

The lead program zolucatetide plans to start a phase 3 trial for desmoid tumors, which are noncancerous growths with few available therapies, during the first half of next year. The candidate has already been evaluated in over 150 patients with encouraging findings across several tumor types, as noted in the company prospectus.

Zolucatetide participates in four phase 1 trials covering hepatocellular carcinoma and colorectal cancer. Additional candidates remain in preclinical development, with plans to broaden the platform beyond oncology into other treatment fields.

Parabilis states that Helicons represent the sole current approach permitting cell penetration and binding to flat surfaces. This capacity to convert previously untreatable targets into viable ones holds substantial promise, especially if extended to numerous therapeutic areas. Roughly 80 percent of confirmed disease targets remain untreatable by existing methods, per company data.

Parabilis reports widening losses

Funds from the IPO will support the phase 3 trial for zolucatetide plus earlier studies in additional indications and foundational research. Losses widened to 145 million dollars last year while research and development expenses reached 125 million dollars. Such trends are typical for biotechs at this development stage. Ongoing spending requirements introduce risk for Parabilis and similar companies.

Given these factors and the recent double-digit IPO gain, does this represent a late entry point? The firm presents compelling and potentially transformative technology, yet several years may pass before any success generates revenue. Therefore Parabilis may not suit conservative investors regardless of share price.

For aggressive investors seeking a biotech with long-term upside potential and willingness to hold positions over multiple years, Parabilis could fit. Even so, there is no requirement to buy immediately following the strong debut. A better approach involves waiting for a price pullback before entering.

Where to place 1000 dollars at present

When our research group identifies a stock opportunity, it often benefits investors to consider it. Stock Advisors overall average return stands at 926 percent, far exceeding the 203 percent return of the S and P 500.

The team recently identified the 10 top stocks for investors to consider now, available upon joining Stock Advisor.

View the stocks

Stock Advisor returns as of June 12, 2026.

Adria Cimino holds no positions in any mentioned stocks. The Motley Fool maintains positions in and recommends Moderna. The Motley Fool recommends Johnson and Johnson. The Motley Fool maintains a disclosure policy.

The views and opinions expressed here belong to the author and do not necessarily represent those of Nasdaq Inc.